Ignite Creation Date:
2024-05-06 @ 3:18 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04591002
Status:
WITHDRAWN
Last Update Posted:
2023-05-12
First Post:
2020-09-08
Brief Title:
Osimertinib to Suppress the Progression of GGNEGFR Mutation-positive
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
A Phase II Open Label Randomized Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule GGN in Other Lobes After Curative Resection for Actionable EGFR Mutation-positive Stage I Lung Adenocarcinoma
Status:
WITHDRAWN
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Further consultation is required we plan to submit it again as a new project and proceed
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study designed to assess the efficacy of osimertinib 80 mg orally once daily to suppress the progression of remaining GGNs in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None